Sara A. Hurvitz, MD
Historically, a diagnosis of HER2-positive breast cancer left a patient with a grim outlook, but therapeutic advances over the past 10 to 15 years have dramatically altered the landscape, explained Sara A. Hurvitz, MD.
, Hurvitz discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.
OncLive: How have HER2-targeted therapies improved outcomes for patients with this breast cancer subtype?
: It has literally altered the natural history of this disease; without HER2-targeted therapies, it has among the worst prognoses. There are new therapies that have been FDA approved over the last 1.5 years or so. Neratinib is approved for 1 year after completing trastuzumab and chemotherapy. Pertuzumab is approved for 1 year given concurrently with trastuzumab. Figuring out who to use these agents for is a bit tricky.
... to read the full story